TY - JOUR AU - Sundaramurthi, Husvinee AU - Tonelotto, Valentina AU - Wynne, Kieran AU - O'Connell, Fiona AU - O’Reilly, Eve AU - Costa-Garcia, Marcel AU - Kovácsházi, Csenger AU - Kittel, Ágnes AU - Marcone, Simone AU - Blanco, Alfonso AU - Pállinger, Éva AU - Hambalkó, Szabolcs AU - Piulats Rodriguez, Jose Maria AU - Ferdinandy, Péter AU - O'Sullivan, Jacintha AU - Matallanas, David AU - Jensen, Lasse D. AU - Giricz, Zoltán AU - Kennedy, Breandán N. TI - Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes JF - OPEN RESEARCH EUROPE J2 - OPEN RES EUROPE VL - 3 PY - 2023 PG - 25 SN - 2732-5121 DO - 10.12688/openreseurope.15973.2 UR - https://m2.mtmt.hu/api/publication/34385416 ID - 34385416 AB - Background Uveal melanoma is a poor prognosis cancer. Ergolide, a sesquiterpene lactone isolated from Inula Brittanica , exerts anti-cancer properties. The objective of this study was to 1) evaluate whether ergolide reduced metastatic uveal melanoma (MUM) cell survival/viability in vitro and in vivo ; and 2) to understand the molecular mechanism of ergolide action. Methods Ergolide bioactivity was screened via long-term proliferation assay in UM/MUM cells and in zebrafish MUM xenograft models. Mass spectrometry profiled proteins modulated by ergolide within whole cell or extracellular vesicle (EVs) lysates of the OMM2.5 MUM cell line. Protein expression was analyzed by immunoblots and correlation analyses to UM patient survival used The Cancer Genome Atlas (TCGA) data. Results Ergolide treatment resulted in significant, dose-dependent reductions (48.5 to 99.9%; p <0.0001) in OMM2.5 cell survival in vitro and of normalized primary zebrafish xenograft fluorescence (56%; p <0.0001) in vivo , compared to vehicle controls. Proteome-profiling of ergolide-treated OMM2.5 cells, identified 5023 proteins, with 52 and 55 proteins significantly altered at 4 and 24 hours, respectively ( p <0.05; fold-change >1.2). Immunoblotting of heme oxygenase 1 (HMOX1) and growth/differentiation factor 15 (GDF15) corroborated the proteomic data. Additional proteomics of EVs isolated from OMM2.5 cells treated with ergolide, detected 2931 proteins. There was a large overlap with EV proteins annotated within the Vesiclepedia compendium. Within the differentially expressed proteins, the proteasomal pathway was primarily altered. Interestingly, BRCA2 and CDKN1A Interacting Protein (BCCIP) and Chitinase Domain Containing 1 (CHID1), were the only proteins significantly differentially expressed by ergolide in both the OMM2.5 cellular and EV isolates and they displayed inverse differential expression in the cells versus the EVs. Conclusions Ergolide is a novel, promising anti-proliferative agent for UM/MUM. Proteomic profiling of OMM2.5 cellular/EV lysates identified candidate pathways elucidating the action of ergolide and putative biomarkers of UM, that require further examination. LA - English DB - MTMT ER - TY - JOUR AU - Benke, Márton AU - Zeöld, Anikó AU - Kittel, Ágnes AU - Khamari, Delaram AU - Hritz, István AU - Horváth, Miklós AU - Keczer, Bánk AU - Borka, Katalin AU - Szűcs, Ákos AU - Wiener, Zoltán TI - MiR-200b categorizes patients into pancreas cystic lesion subgroups with different malignant potential JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-023-47129-1 UR - https://m2.mtmt.hu/api/publication/34371433 ID - 34371433 AB - Extracellular vesicles (EV) carry their cargo in a membrane protected form, however, their value in early diagnostics is not well known. Although pancreatic cysts are heterogeneous, they can be clustered into the larger groups of pseudocysts (PC), and serous and mucinous pancreatic cystic neoplasms (S-PCN and M-PCN, respectively). In contrast to PCs and S-PCNs, M-PCNs may progress to malignant pancreatic cancers. Since current diagnostic tools do not meet the criteria of high sensitivity and specificity, novel methods are urgently needed to differentiate M-PCNs from other cysts. We show that cyst fluid is a rich source of EVs that are positive and negative for the EV markers CD63 and CD81, respectively. Whereas we found no difference in the EV number when comparing M-PCN with other pancreatic cysts, our EV-based biomarker identification showed that EVs from M-PCNs had a higher level of miR-200b. We also prove that not only EV-derived, but also total cyst fluid miR-200b discriminates patients with M-PCN from other pancreatic cysts with a higher sensitivity and specificity compared to other diagnostic methods, providing the possibility for clinical applications. Our results show that measuring miR-200b in cyst fluid-derived EVs or from cyst fluid may be clinically important in categorizing patients. LA - English DB - MTMT ER - TY - JOUR AU - Mladenović, Danilo AU - Khamari, Delaram AU - Kittel, Ágnes AU - Koort, Kairi AU - Buzás, Edit Irén AU - Zarovni, Nataša TI - Acidification of blood plasma facilitates the separation and analysis of extracellular vesicles JF - JOURNAL OF THROMBOSIS AND HAEMOSTASIS J2 - J THROMB HAEMOST VL - 21 PY - 2023 IS - 4 SP - 1032 EP - 1042 PG - 11 SN - 1538-7933 DO - 10.1016/j.jtha.2023.01.007 UR - https://m2.mtmt.hu/api/publication/33667258 ID - 33667258 N1 - HansaBioMed Life Sciences Ltd., Tallinn, Estonia School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary Eötvös Loránd Research Network, Translational Extracellular Vesicle Research Group, Semmelweis University, Budapest, Hungary Eötvös Loránd Research Network, Institute of Experimental Medicine, Budapest, Hungary Hungarian Center of Excellence Molecular Medicine, Extracellular Vesicle Research Group, Semmelweis University, Budapest, Hungary Exosomics SpA, Siena, Italy Cited By :1 Export Date: 13 February 2024 CODEN: JTHOA Correspondence Address: Zarovni, N.; HansaBioMed Life Sciences Ltd., Mäealuse 2/1, Estonia; email: nzarovni@exosomics.eu Chemicals/CAS: Biomarkers; Lipopolysaccharides; Lipoproteins Funding details: 2014-2020.4.02.21-0398 Funding details: Horizon 2020 Framework Programme, H2020, 739593, TKP-2021-Terapias-EGA-23 Funding details: Hungarian Scientific Research Fund, OTKA, NVKP_16-1-2016- 0017, VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2017-00016 Funding details: Horizon 2020, H2020-MSCA-ITN-2017-722148, NVKP_16-1-2016-0017 Funding text 1: This work was supported by following funding programs: European Union’s Horizon 2020 research and innovation program under the grant agreement number H2020-MSCA-ITN-2017-722148 (TRAIN EV); European Regional Development Fund Enterprise Estonia’s Applied Research Program under the grant agreement number 2014-2020.4.02.21-0398 (EVREM), National Scientific Research Program of Hungary (OTKA) NVKP_16-1-2016- 0017, Higher Education Institutional Excellence Program – Therapeutic development, Ministry for National Economy of Hungary under the grant number VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2017-00016, European Union’s Horizon 2020 research and innovation program under the grant agreement number 739593, and the grant TKP-2021-Terapias-EGA-23. Funding text 2: This work was supported by following funding programs: European Union's Horizon 2020 research and innovation program under the grant agreement number H2020-MSCA-ITN-2017-722148 (TRAIN EV); European Regional Development Fund Enterprise Estonia's Applied Research Program under the grant agreement number 2014-2020.4.02.21-0398 (EVREM), National Scientific Research Program of Hungary (OTKA) NVKP_16-1-2016- 0017, Higher Education Institutional Excellence Program – Therapeutic development, Ministry for National Economy of Hungary under the grant number VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2017-00016, European Union's Horizon 2020 research and innovation program under the grant agreement number 739593, and the grant TKP-2021-Terapias-EGA-23.This work was supported by following funding programmes: European Union's Horizon 2020 research and innovation programme under the grant agreement number H2020-MSCA-ITN-2017-722148 (TRAIN EV); European Regional Development Fund Enterprise Estonia's Applied Research Program under the grant agreement number 2014-2020.4.02.21-0398 (EVREM), National Scientific Research Program of Hungary (OTKA) NVKP_16-1-2016-0017, Higher Education Institutional Excellence Program – Therapeutic development, Ministry for National Economy of Hungary under the grant number VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2017-00016, European Union's Horizon 2020 research and innovation program under the grant agreement number 739593, and the grant TKP-2021-Terapias-EGA-23. D.M. and D.K. contributed equally to this work. Conceptualization, D.M. and N.Z.; Methodology; D.M. and D.K.; Data Curation, D.M. D.K. and A.K.; Formal Analysis, D.M. D.K. and A.K.; Validation, D.M. D.K. E.I.B. and N.Z.; Writing—Original Draft Preparation, D.M. and D.K.; Writing—Review and Editing N.Z. E.I.B. A.K. and K.K.; Supervision, N.Z. E.I.B. and K.K. All authors read and approved the final manuscript. There are no competing interests to disclose. Funding information Funding text 3: This work was supported by following funding programmes: European Union’s Horizon 2020 research and innovation programme under the grant agreement number H2020-MSCA-ITN-2017-722148 (TRAIN EV); European Regional Development Fund Enterprise Estonia’s Applied Research Program under the grant agreement number 2014-2020.4.02.21-0398 (EVREM), National Scientific Research Program of Hungary (OTKA) NVKP_16-1-2016-0017, Higher Education Institutional Excellence Program – Therapeutic development, Ministry for National Economy of Hungary under the grant number VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2017-00016, European Union’s Horizon 2020 research and innovation program under the grant agreement number 739593, and the grant TKP-2021-Terapias-EGA-23. LA - English DB - MTMT ER - TY - JOUR AU - Valcz, Gábor AU - Újvári, Beáta AU - Buzás, Edit Irén AU - Krenács, Tibor AU - Spisák, Sándor AU - Kittel, Ágnes AU - Tulassay, Zsolt AU - Igaz, Péter AU - Takács, István AU - Molnár, Béla TI - Small extracellular vesicle DNA-mediated horizontal gene transfer as a driving force for tumor evolution: Facts and riddles JF - FRONTIERS IN ONCOLOGY J2 - FRONT ONCOL VL - 12 PY - 2022 PG - 9 SN - 2234-943X DO - 10.3389/fonc.2022.945376 UR - https://m2.mtmt.hu/api/publication/33070261 ID - 33070261 N1 - Cited By :2 Export Date: 19 May 2023 Correspondence Address: Valcz, G.; MTA-SE Molecular Medicine Research Group, Hungary; email: valcz.gabor@med.semmelweis-univ.hu Chemicals/CAS: DNA, 9007-49-2 Funding details: Semmelweis Egyetem Funding details: Emberi Eroforrások Minisztériuma, EMMI Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH Funding text 1: This work was funded by the NVKP_16-1-2016-0004 grant of the Hungarian National Research, Development and Innovation Office (NKFIH), as well as the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the molecular biology thematic program of Semmelweis University. AB - The basis of the conventional gene-centric view on tumor evolution is that vertically inherited mutations largely define the properties of tumor cells. In recent years, however, accumulating evidence shows that both the tumor cells and their microenvironment may acquire external, non-vertically inherited genetic properties via horizontal gene transfer (HGT), particularly through small extracellular vesicles (sEVs). Many phases of sEV-mediated HGT have been described, such as DNA packaging into small vesicles, their release, uptake by recipient cells, and incorporation of sEV-DNA into the recipient genome to modify the phenotype and properties of cells. Recent techniques in sEV separation, genome sequencing and editing, as well as the identification of new secretion mechanisms, shed light on a number of additional details of this phenomenon. Here, we discuss the key features of this form of gene transfer and make an attempt to draw relevant conclusions on the contribution of HGT to tumor evolution. LA - English DB - MTMT ER - TY - JOUR AU - Sallai, Imre AU - Marton, Nikolett AU - Szatmári, Attila AU - Kittel, Ágnes AU - Nagy, György AU - Buzás, Edit Irén AU - Khamari, Delaram AU - Komlósi, Zsolt AU - Kristóf, Katalin AU - Drahos, László AU - Turiák, Lilla AU - Sugár, Simon Nándor AU - Veres, Dániel AU - Kendoff, Daniel AU - Zahár, Ákos AU - Skaliczki, Gábor TI - Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection JF - PLOS ONE J2 - PLOS ONE VL - 17 PY - 2022 IS - 5 PG - 18 SN - 1932-6203 DO - 10.1371/journal.pone.0268076 UR - https://m2.mtmt.hu/api/publication/32813061 ID - 32813061 N1 - Department of Orthopaedics, Semmelweis University, Budapest, Hungary Jahn Ferenc Hospital, Budapest, Hungary Institute of Experimental Medicine, Budapest, Hungary Department of Rheumatology and Clinical Immunology, Semmelweis University, Budapest, Hungary Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary HCEMM Extracellular Vesicle Research Group, Semmelweis University, Budapest, Hungary ELKH-SE Immune-Proteogenomics Extracellular Vesicle Research Group, Budapest, Hungary Clinical Microbiological Diagnostic Laboratory, Semmelweis University, Budapest, Hungary MS Proteomics Research Group, Research Centre for Natural Sciences, Budapest, Hungary Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary Helios Klinikum Berlin-Buch, Berlin, Germany Helios Klinikum Emil von Behring, Berlin, Germany Cited By :3 Export Date: 13 February 2024 CODEN: POLNC Correspondence Address: Sallai, I.; Department of Orthopaedics, Hungary; email: sallai.imre@semmelweis-univ.hu Chemicals/CAS: lactoferrin, 55599-62-7; lysozyme, 9001-63-2; myeloperoxidase; lipocortin 5, 111237-10-6; Annexin A5; Biomarkers Funding details: EFOP-3.6.3-VEKOP-16-2017-00009 Funding details: Horizon 2020 Framework Programme, H2020, 739593 Funding details: Semmelweis Egyetem Funding text 1: This work was supported by the ENDOVerein Hamburg, Germany. (and EFOP-3.6.3-VEKOP-16-2017-00009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like acknowledge the help of the Department of Laboratory Medicine (Semmelweis University, Budapest, Hungary) especially Barna Vásárhelyi, Ibolya Kocsis and Balázs Szalay. On behalf of Project "Proteomikai BigData értékelése" we thank for the usage of ELKH Cloud (https://science-cloud.hu/) that significantly helped us achieving the results published in this paper. AB - Background Extracellular vesicles (EVs) are considered as crucial players in a wide variety of biological processes. Although their importance in joint diseases or infections has been shown by numerous studies, much less is known about their function in periprosthetic joint infection (PJI). Our aim was to investigate activated polymorphonuclear (PMN)-derived synovial EVs in patients with PJI. Questions/Purposes (1) Is there a difference in the number and size of extracellular vesicles between periprosthetic joint aspirates of patients with PJI and aseptic loosening? (2) Are these vesicles morphologically different in the two groups? (3) Are there activated PMN-derived EVs in septic samples evaluated by flow cytometry after CD177 labelling? (4) Is there a difference in the protein composition carried by septic and aseptic vesicles? Methods Thirty-four patients (n = 34) were enrolled into our investigation, 17 with PJI and 17 with aseptic prosthesis loosening. Periprosthetic joint fluid was aspirated and EVs were separated. Samples were analysed by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM) and flow cytometry (after Annexin V and CD177 labelling). The protein content of the EVs was studied by mass spectrometry (MS). Results NTA showed particle size distribution in both groups between 150 nm and 450 nm. The concentration of EVs was significantly higher in the septic samples (p = 0.0105) and showed a different size pattern as compared to the aseptic ones. The vesicular nature of the particles was confirmed by TEM and differential detergent lysis. In the septic group, FC analysis showed a significantly increased event number both after single and double labelling with fluorochrome conjugated Annexin V (p = 0.046) and Annexin V and anti-CD177 (p = 0.0105), respectively. MS detected a significant difference in the abundance of lactotransferrin (p = 0.00646), myeloperoxidase (p = 0.01061), lysozyme C (p = 0.04687), annexin A6 (p = 0.03921) and alpha-2-HS-glycoprotein (p = 0.03146) between the studied groups. Conclusions An increased number of activated PMN derived EVs were detected in the synovial fluid of PJI patients with a characteristic size distribution and a specific protein composition. The activated PMNs-derived extracellular vesicles can be potential biomarkers of PJI. Copyright: © 2022 Sallai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. LA - English DB - MTMT ER - TY - JOUR AU - Walter, Fruzsina AU - Harazin, András AU - Tóth, Andrea AU - Veszelka, Szilvia AU - Santa Maria, Anaraquel AU - Barna, Lilla AU - Kincses, András AU - Biczo, G AU - Balla, Zsolt AU - Kui, Balázs AU - Maléth, József AU - Cervenak, László AU - Tubak, Vilmos AU - Kittel, Ágnes AU - Rakonczay, Zoltán AU - Deli, Mária Anna TI - Blood–brain barrier dysfunction in l-ornithine induced acute pancreatitis in rats and the direct effect of l-ornithine on cultured brain endothelial cells JF - FLUIDS AND BARRIERS OF THE CNS J2 - FLUIDS BARRIERS CNS VL - 19 PY - 2022 IS - 1 PG - 20 SN - 2045-8118 DO - 10.1186/s12987-022-00308-0 UR - https://m2.mtmt.hu/api/publication/32667372 ID - 32667372 N1 - Institute of Biophysics, Biological Research Centre, Temesvári krt. 62, Szeged, 6726, Hungary Department of Medicine, University of Szeged, Kálvária sgt 57, Szeged, 6725, Hungary Department of Pathophysiology, University of Szeged, Semmelweis u. 1, Szeged, 6701, Hungary HAS-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Dóm sqr. 10, Szeged, 6720, Hungary HCEMM-SZTE Molecular Gastroenterology Research Group, University of Szeged, Dóm sqr. 10, Szeged, 6720, Hungary Department of Internal Medicine and Hematology, Research Laboratory, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary Creative Laboratory Ltd, Temesvári krt. 62, Szeged, 6726, Hungary Institute of Experimental Medicine, Eötvös Loránd Research Network, Szigony u. 43, Budapest, 1083, Hungary Wyss Institute for Biologically Inspired Engineering at Harvard University, 3 Blackfan Circle, Boston, MA 02115, United States Department of Biomedicine, Faculty of Health, Aarhus University, Høegh-Guldbergs Gade 10, Aarhus C, 8000, Denmark Institute of Applied Sciences, Department of Environmental Biology and Education, Juhász Gyula Faculty of Education, University of Szeged, Boldogasszony sgt. 6, Szeged, 6725, Hungary Cited By :1 Export Date: 23 November 2022 Correspondence Address: Deli, M.A.; Institute of Biophysics, Temesvári krt. 62, Hungary; email: deli.maria@brc.hu LA - English DB - MTMT ER - TY - JOUR AU - Hegyesi, Hargita AU - Pállinger, Éva AU - Mecsei, Szabina AU - Hornyák, Balázs AU - Kovácsházi, Csenger AU - Brenner, Gábor AU - Giricz, Zoltán AU - Pálóczi, Krisztina AU - Kittel, Ágnes AU - Tóvári, József AU - Turiák, Lilla AU - Khamari, Delaram AU - Ferdinandy, Péter AU - Buzás, Edit Irén TI - Circulating cardiomyocyte-derived extracellular vesicles reflect cardiac injury during systemic inflammatory response syndrome in mice JF - CELLULAR AND MOLECULAR LIFE SCIENCES J2 - CELL MOL LIFE SCI VL - 79 PY - 2022 IS - 2 PG - 15 SN - 1420-682X DO - 10.1007/s00018-021-04125-w UR - https://m2.mtmt.hu/api/publication/32611202 ID - 32611202 N1 - Funding Agency and Grant Number: Semmelweis University; National Research, Development and Innovation Office NKFIH, HungaryNational Research, Development & Innovation Office (NRDIO) - Hungary [NVKP_16-1-20160017]; Hungarian Scientific Research FundOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [OTKA K120237, VEKOP-2.3.2-16-2016-000002, VEKOP-2.3.3-15-2017-00016, H2020-MSCA-ITN-2017-722148 TRAIN EV]; Higher Education Excellence Program (FIKP) Therapeutic Thematic Programme; Hungarian Thematic Excellence Programme [TKP2020-NKA-26]; EU's Horizon 2020 research and innovation program [739593]; [VEKOP-2.3.3-15-2016-00006] Funding text: Open access funding provided by Semmelweis University. This work was supported by National Research, Development and Innovation Office NKFIH, Hungary, NVKP_16-1-20160017, the Hungarian Scientific Research Fund (OTKA K120237), VEKOP-2.3.2-16-2016-000002, VEKOP-2.3.3-15-2017-00016, H2020-MSCA-ITN-2017-722148 TRAIN EV and Higher Education Excellence Program (FIKP) Therapeutic Thematic Programme. This study was supported by the Hungarian Thematic Excellence Programme No TKP2020-NKA-26. The project has received funding from the EU's Horizon 2020 research and innovation program under Grant agreement No. 739593. The research was also supported by VEKOP-2.3.3-15-2016-00006. LA - English DB - MTMT ER - TY - JOUR AU - Németh, Krisztina AU - Varga, Zoltán AU - Lenzinger, Dorina AU - Visnovitz, Tamás AU - Koncz, Anna AU - Hegedűs, Nikolett AU - Kittel, Ágnes AU - Máthé, Domokos AU - Szigeti, Krisztián AU - Lőrincz, Péter AU - O'Neill, Clodagh AU - Dwyer, Róisín AU - Liu, Zhonglin AU - Buzás, Edit Irén AU - Tamási, Viola TI - Extracellular vesicle release and uptake by the liver under normo- and hyperlipidemia JF - CELLULAR AND MOLECULAR LIFE SCIENCES J2 - CELL MOL LIFE SCI VL - 78 PY - 2021 IS - 23 SP - 7589 EP - 7604 PG - 16 SN - 1420-682X DO - 10.1007/s00018-021-03969-6 UR - https://m2.mtmt.hu/api/publication/32289889 ID - 32289889 N1 - Edit I. Buzás and Viola Tamási shares last authorship AB - Liver plays a central role in elimination of circulating extracellular vesicles (EVs), and it also significantly contributes to EV release. However, the involvement of the different liver cell populations remains unknown. Here, we investigated EV uptake and release both in normolipemia and hyperlipidemia. C57BL/6 mice were kept on high fat diet for 20-30 weeks before circulating EV profiles were determined. In addition, control mice were intravenously injected with 99mTc-HYNIC-Duramycin labeled EVs, and an hour later, biodistribution was analyzed by SPECT/CT. In vitro, isolated liver cell types were tested for EV release and uptake with/without prior fatty acid treatment. We detected an elevated circulating EV number after the high fat diet. To clarify the differential involvement of liver cell types, we carried out in vitro experiments. We found an increased release of EVs by primary hepatocytes at concentrations of fatty acids comparable to what is characteristic for hyperlipidemia. When investigating EV biodistribution with 99mTc-labeled EVs, we detected EV accumulation primarily in the liver upon intravenous injection of mice with medium (326.3 ± 19.8 nm) and small EVs (130.5 ± 5.8 nm). In vitro, we found that medium and small EVs were preferentially taken up by Kupffer cells, and liver sinusoidal endothelial cells, respectively. Finally, we demonstrated that in hyperlipidemia, there was a decreased EV uptake both by Kupffer cells and liver sinusoidal endothelial cells. Our data suggest that hyperlipidema increases the release and reduces the uptake of EVs by liver cells. We also provide evidence for a size-dependent differential EV uptake by the different cell types of the liver. The EV radiolabeling protocol using 99mTc-Duramycin may provide a fast and simple labeling approach for SPECT/CT imaging of EVs biodistribution. LA - English DB - MTMT ER - TY - JOUR AU - Jelemenský, Marek AU - Kovácsházi, Csenger AU - Ferenczyová, Kristína AU - Hofbauerová, Monika AU - Kiss, Bernadett AU - Pállinger, Éva AU - Kittel, Ágnes AU - Sayour, Viktor Nabil AU - Görbe, Anikó AU - Pelyhe, Csilla AU - Hambalkó, Szabolcs AU - Kindernay, Lucia AU - Barančík, Miroslav AU - Ferdinandy, Péter AU - Barteková, Monika AU - Giricz, Zoltán TI - Helium Conditioning Increases Cardiac Fibroblast Migration Which Effect Is Not Propagated via Soluble Factors or Extracellular Vesicles JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 22 PY - 2021 IS - 19 PG - 13 SN - 1661-6596 DO - 10.3390/ijms221910504 UR - https://m2.mtmt.hu/api/publication/32282104 ID - 32282104 N1 - Export Date: 24 October 2021 LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Eszter Ágnes AU - Turiák, Lilla AU - Visnovitz, Tamás AU - Cserép, Csaba AU - Türk-Mázló, Anett AU - Sódar, Barbara AU - Försönits, András AU - Petővári, Gábor AU - Sebestyén, Anna AU - Komlósi, Zsolt AU - Drahos, László AU - Kittel, Ágnes AU - Nagy, György AU - Bácsi, Attila AU - Dénes, Ádám AU - Song Gho, Yong AU - Szabó-Taylor, Katalin AU - Buzás, Edit Irén TI - Formation of a protein corona on the surface of extracellular vesicles in blood plasma JF - JOURNAL OF EXTRACELLULAR VESICLES J2 - J EXTRACELLULAR VESICL VL - 10 PY - 2021 IS - 11 PG - 26 SN - 2001-3078 DO - 10.1002/jev2.12140 UR - https://m2.mtmt.hu/api/publication/32189675 ID - 32189675 N1 - Katalin É Szabó-Taylor and Edit I Buzás contributed equally. Funding information National Research, Development and Innovation Office NKFIH, Hungary, Grant/Award Numbers: OTKA11958, OTKA120237, OTKA125337, OTKA K131479, OTKA PD 121187, OTKA FK 131603, OTKA 131762, NVKP_16-1-2016-0017; Higher Education Institutional Excellence Program – Therapeutic development, Grant/Award Numbers:ÚNKP-19-3-I-SE-45, ÚNKP-20-5; New National Excellence Program of the Ministry for Innovation and Technology; Ministry for National Economy of Hungary, Grant/Award Numbers: VEKOP-2.3.2-16-2016-00002, VEKOP-2.3.3-15-2016-00016, EFOP-3.6.3-VEKOP-16-2017-00009; Az orvos-,egészségtudományi- és gyógyszerészképzés tudományos muhelyeinek fejlesztése; European ̋Commission, Grant/Award Number: H2020-MSCA-ITN-2017-722148 TRAIN EV; Hungarian Academy of Sciences: János Bolyai Research Schol- arship and “Momentum”, Grant/Award Number: LP2016-4/2016; European Research Council, Grant/Award Numbers: ERC-CoG 724994, H2020-ITN-2018-813294-ENTRAIN; EU’s Horizon 2020 research and innovation program, Grant/Award Number: 739593 LA - English DB - MTMT ER -